Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis

D Sussman, A Yehoshua, J Kowalski, W Lee, J Kish, S Chaudhari, B Murray, D Sussman, A Yehoshua, J Kowalski, W Lee, J Kish, S Chaudhari, B Murray

Abstract

Background: Adherence and persistence rates of anticholinergic (ACH) therapies have been well described. To date, few studies describe these metrics for mirabegron in patients with overactive bladder.

Methods: This retrospective analysis of MarketScan® database assessed adherence and persistence of patients receiving either mirabegron or ACH. Study eligibility required an index date (first prescription filled) between July 2012 and June 2013 with 12 months of continuous enrolment preindex date and 12 months of follow-up. Adherence was defined as a proportion of days covered of ≥ 80% among patients with at least 2 fills of index medication. Persistence measures included treatment failure described as either treatment discontinuation (medication supply gap ≥ 30 days) or switching to a different medication. A medication supply gap of ≥ 45 days was used as a sensitivity analysis.

Results: The mean age of mirabegron users (n = 4037) was 67 years and 43% were ACH naïve while the mean age of ACH users was 62 years (n = 67,943). Over the 12-month follow-up period, 44% of patients treated with mirabegron and 31% of patients treated with ACH were adherent to their indexed medications. Treatment failure was 81% for mirabegron and 88% for ACH. Most mirabegron treatment failures were because of treatment discontinuation (67%) versus switching to ACH therapy (14%). The ACH discontinuation rate was 84% and treatment switching rate was 4%. The mean (standard deviation) time to treatment failure was 143 (130) days for mirabegron and 69 (69) days for ACH. Adherence and persistence patterns were similar in the sensitivity analysis using a ≥ 45-day supply gap threshold.

Conclusions: This real-world study demonstrated low adherence and persistence to mirabegron similar to ACH therapies.

© 2017 Allergan. International Journal of Clinical Practice Published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Patient selection using MarketScan® Claims Database from July 2011 to June 2014

References

    1. Gormley EA, Lightner DJ, Burgio KL et al. Diagnosis and treatment of overactive bladder (non‐neurogenic) in adults: AUA/SUFU guideline. J Urol 2012; 188: 2455–63.
    1. Parasuraman S, Muralidharan S, Jaya Raja Kumar K. Mirabegron ‐ a beta‐3 adrenergic agonist for overactive baldder syndrome: a review. Int J Res Pharm Sci 2013; 4: 593–6.
    1. Coyne KS, Sexton CC, Vats V et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2011; 77: 1081–7.
    1. Moon SJ, Kim YT, Lee TY et al. The influence of an overactive bladder on falling: a study of females aged 40 and older in the community. Int Neurourol J 2011; 15: 41–7.
    1. Benner JS, Nichol MB, Rovner ES et al. Patient‐reported reasons for discontinuing overactive bladder medication. BJU Int 2010; 105: 1276–82.
    1. Brubaker L, Fanning K, Goldberg EL et al. Predictors of discontinuing overactive bladder medications. BJU Int 2010; 105: 1283–90.
    1. Gomelsky A, Dmochowski RR. Update on the management of overactive bladder: patient considerations and adherence. Open Access J Urol 2010; 3: 7–17.
    1. Chancellor MB, Migliaccio‐Walle K, Bramley TJ et al. Long‐term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther 2013; 35: 1744–51.
    1. Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database. Acta Obstet Gynecol Scand 2013; 92: 1208–15.
    1. Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012; 110: 1767–74.
    1. D'Souza AO, Smith MJ, Miller LA et al. Persistence, adherence, and switch rates among extended‐release and immediate‐release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008; 14: 291–301.
    1. Veenboer PW, Bosch JL. Long‐term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 2014; 191: 1003–8.
    1. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998; 20: 764–71.
    1. Leong RK, De Wachter SG, van Kerrebroeck PE. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Urol Int 2010; 84: 245–53.
    1. Novara G, Cornu JN. Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns. Eur Urol 2013; 63: 306–8.
    1. Cox L, Cameron AP. OnabotulinumtoxinA for the treatment of overactive bladder. Res Rep Urol 2014; 6: 79–89.
    1. White N, Iglesia CB. Overactive Bladder. Obstet Gynecol Clin North Am 2016; 43: 59–68.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren